drugset / Trial / NCT06116786

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

NCT06116786

Phase 1 Recruiting 126 enrolled Johnson & Johnson Enterprise Innovation Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.

Timeline

Start
2023-11-27
Primary completion
2027-04-14
Completion
2029-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-86974680 Unknown
Background Cetrelimab Monoclonal antibody